19250-03-4

Usage

Uses

Used in Organic Synthesis:
(4-phenylphenyl)thiourea is utilized as a reagent in organic synthesis for its catalytic properties. It plays a crucial role in the formation of heterocyclic compounds, which are essential in the development of pharmaceuticals, agrochemicals, and other specialty chemicals.
Used in Pharmaceutical Industry:
In the pharmaceutical sector, (4-phenylphenyl)thiourea serves as a precursor for the synthesis of various drugs. Its ability to participate in the formation of complex molecular structures makes it a valuable component in the creation of new therapeutic agents.
However, it is important to note that (4-phenylphenyl)thiourea has been identified as a toxic substance. Ingestion or inhalation can lead to toxicity, and it can cause skin and eye irritation. Therefore, proper handling and safety measures are essential when working with (4-phenylphenyl)thiourea in any application.

InChI:InChI=1/C13H12N2S/c14-13(16)15-12-8-6-11(7-9-12)10-4-2-1-3-5-10/h1-9H,(H3,14,15,16)

Upstream product

• 1147550-11-5 ammonium thiocyanate 
• 92-67-1 4-phenylalanine 
• 1430796-58-9 C₁₃H₁₁NS₂*C₆H₁₂N₂ 
• 106-40-1 4-bromo-aniline 
• 98-80-6 phenylboronic acid 
• 1510-24-3 1-isothiocyanato-4-phenylbenzene 
• 45943-14-4 benzoyl isothiocyanate 
• 874298-48-3 C₁₆H₁₆N₂O₂S 

Downstream Products

• 874298-49-4 C₂₅H₂₀N₂O₃S 
• 73901-13-0 2-amino-3-methyl-6-phenyl-benzothiazolium-betaine 
• 101937-36-4 N-biphenyl-4-yl-N'-(4-bromo-phenyl)-thiourea 
• 101894-73-9 N-biphenyl-4-yl-N'-(4-chloro-phenyl)-thiourea 
• 4474-04-8 N-(1,1'-biphenyl-4-yl)-N'-phenylthiourea 
• 102318-20-7 N-(4-ethoxy-phenyl)-N'-biphenyl-4-yl-thiourea 
• 92-96-6 N,N'-bis-biphenyl-4-yl-thiourea 
• 1510-24-3 1-isothiocyanato-4-phenylbenzene 
• 73458-38-5 6-phenylbenzo[d]thiazole-2-amine 

Relevant academic research and scientific papers

Discovery of aminothiazole derivatives as novel human enterovirus A71 capsid protein inhibitors

Enterovirus A71 (EV-A71), one of the major pathogens that causes hand, foot and mouth disease (HFMD), has seriously threatened the health and safety of young children. In this study, aminothiazole derivatives were synthesized and screened against EV-A71 in Rhabdomyosarcoma (RD) cells. The best compound (12s), with a biphenyl group, showed activity against EV-A71 (EC50: 0.27 μM) but also against a series of different human enteroviruses without significant cytotoxicity (CC50 > 56.2 μM). Mechanistic studies including time-of-drug-addition assays, viral entry assays and microscale thermophoresis (MST) experiments, showed that 12s binds to EV-A71 capsid and blocks the binding between the viral protein VP1 and the relevant human scavenger receptor class B member 2 (hSCARB2).

Design, synthesis, X-ray crystallographic analysis, and biological evaluation of thiazole derivatives as potent and selective inhibitors of human dihydroorotate dehydrogenase

Human dihydroorotate dehydrogenase (HsDHODH) is a flavin-dependent mitochondrial enzyme that has been certified as a potential therapeutic target for the treatment of rheumatoid arthritis and other autoimmune diseases. On the basis of lead compound 4, which was previously identified as potential HsDHODH inhibitor, a novel series of thiazole derivatives were designed and synthesized. The X-ray complex structures of the promising analogues 12 and 33 confirmed that these inhibitors bind at the putative ubiquinone binding tunnel and guided us to explore more potent inhibitors, such as compounds 44, 46, and 47 which showed double digit nanomolar activities of 26, 18, and 29 nM, respectively. Moreover, 44 presented considerable anti-inflammation effect in vivo and significantly alleviated foot swelling in a dose-dependent manner, which disclosed that thiazole-scaffold analogues can be developed into the drug candidates for the treatment of rheumatoid arthritis by suppressing the bioactivity of HsDHODH.

DIPHENYLAMINE-SUBSTITUTED SALICYLTHIAZOLE DERIVATIVES AND RELATED COMPOUNDS AS PHOSPHOTYROSINE PHOSPHATASE 1B (PTP1B) INHIBITORS FOR USING AS BLOOD-SUGAR DECREASING ACTIVE INGREDIENTS FOR TREATING DIABETES

The aim of the invention is to provide compounds having a therapeutic blood-sugar decreasing effect. Said compounds are suitable especially for the prevention and treatment of pancreatic diabetes. To this end, the invention relates to compounds of formula

SUBSTITUTED ARYLTHIOUREA DERIVATIVES USEFUL AS INHIBITORS OF VIRAL REPLICATION

Substituted arylthiourea compounds of Formula I, and the pharmaceutically acceptable salts of such compounds, useful as antiviral agents, are provided herein. Certain substituted arylthioureas disclosed herein are potent and/ or selective inhibitors of viral replication, particularly Hepatitis C virus replication. Pharmaceutical compositions containing one or more substituted arylthiourea compounds and one or more pharmaceutically acceptable carriers, excipients, or diluents are provided herein. Such pharmaceutical compositions may contain a substituted arylthiourea as the only active agent or may contain a combination of a substituted arylthiourea derivative and one or more other pharmaceutically active agents. Methods of treating Hepatitis C viral infections in mammals are also provided herein.